Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


To Get The Most Out Of Health CER, Hire A Mathematician, Conferees Say

Executive Summary

Economists, mathematicians and behavioral scientists are among the non-health care specialists who could be essential to ensuring the wealth of comparative effectiveness research data available is used to its full potential, according to speakers at a recent CER event.

You may also be interested in...

Pfizer Seeks Insights Into Big Data Analysis, Personalized Medicine Through Optum Labs

Pfizer VP Marc Berger says in an interview that his company joined the Optum Labs collaborative to look for insights on disease progression, help inform personalized medicine activities, and to work with others on developing and testing new methodologies for analyzing big data.

Pharma Use Of Big Data Limited; Firms Need Dedicated Teams, Consultant Urges

Cutting Edge Information recommends that pharma firms have dedicated big data teams; develop prospective big data strategies for using health outcomes, patient-reported outcomes and real-world data; and build research teams around individuals with industry and analytics expertise.

PCORI To Solicit More Head-To-Head Comparative Studies

The Patient-Centered Outcomes Research Institute announces plans to encourage the submission of more proposals for head-to-head clinical comparative effectiveness studies. Among the research topics the institute will encourage are the Institute of Medicine’s top 100 priorities and recommendations from America’s Health Insurance Plans.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts